T2 Biosystems (TTOO) Tops Q3 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
T2 Biosystems Reports Third Quarter 2017 Financial Results and Provides Company Update
November 2, 2017 4:06 PM EDTSubmitted 510(k) Application to the FDA Requesting Market Clearance for T2Bacteria PanelYear over Year Quarterly Product Revenue Growth of 27.4%
LEXINGTON, Mass., Nov. 02, 2017 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ: TTOO), an emerging leader in the development of innovative diagnostic products to improve patient health, announced today operating highlights and financial results for the third quarter ended September 30, 2017. Â
 Third Quarter Business and Financial Performance Highlights:
Reported third quarter total revenue of $1.1 million, in line with guidance. Product revenue of $739,000, was a $159,000 or 27.4% increase from the... More